Literature DB >> 1537056

Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells.

J J Bergers1, W Den Otter, J W De Groot, A W De Blois, H F Dullens, P A Steerenberg, D J Crommelin.   

Abstract

Antigens presented on cell membranes or on liposomes are usually more immunogenic than antigens in soluble form, this being one of the reasons for the weak immunogenicity of extracted tumour-associated transplantation antigens (TATA). The main objective of this study is to solubilize TATA from tumour cells and to present them on a membrane-like structure to the immune system. Crude tumour cell membranes of SL2 lymphosarcoma cells (a spontaneously arising, weakly immunogenic tumour) were solubilized with octylglucoside or sodium deoxycholate, and reconstituted membranes (proteoliposomes) were prepared by detergent removal. Mice immunized s.c. with reconstituted membranes were protected against an i.p. challenge with tumour cells. Although octylglucoside solubilized only 41% of the membrane proteins, the reconstituted membranes were as immunoprotective as crude membranes. (Glyco)proteins were probably the major membrane components in the reconstituted membranes that induce immunoprotection, as mice immunized with preparations constituted of (glyco)lipids from SL2 cells could not reject SL2 cells. If Freund's complete adjuvant was used with the first immunization injection, no potentiation of the elicited immune responses was observed. Besides the membrane TATA, SL2 cells contained an apparently non-membrane-bound TATA, which was found in the cytoplasm. It is concluded that detergent solubilization of membranes and subsequent preparation of reconstituted membranes can be used to obtain membrane tumour-associated antigens that retain activity for induction of protective tumour immunity. The major advantage of this method is that membrane proteins are solubilized and are subsequently presented on a membrane-like structure that resembles the tumour cell membrane. On theoretical and practical grounds it provides a promising alternative for whole-cell vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537056     DOI: 10.1007/bf01741791

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  Purification of papain-solubilized histocompatibility antigens from a cultured human lymphoblastoid line, RPMI 4265.

Authors:  M J Turner; P Cresswell; P Parham; J L Strominger; D L Mann; A R Sanderson
Journal:  J Biol Chem       Date:  1975-06-25       Impact factor: 5.157

Review 2.  Tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

Review 3.  Tumor vaccines.

Authors:  J C Bystryn
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

4.  Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma.

Authors:  G Ritter; E Boosfeld; R Adluri; M Calves; H F Oettgen; L J Old; P Livingston
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

5.  Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

Authors:  M S Mitchell; J Kan-Mitchell; R A Kempf; W Harel; H Y Shau; S Lind
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

6.  Staging, growth properties and metastatic behaviour of a transplantable murine T-cell lymphoma.

Authors:  H F Dullens; J Hilgers; B J Spit; E De Heer; R A De Weger; C D Van Basten; W Den Otter
Journal:  Int J Tissue React       Date:  1982

7.  Differential extraction of tumor-specific transplantation antigen and embryonic antigen from simian virus 40- and adenovirus 7-induced sarcoma cells of hamsters with 1-butanol and 3 M potassium chloride.

Authors:  J H Coggin; L D Gillis; W J Payne
Journal:  J Natl Cancer Inst       Date:  1984-04       Impact factor: 13.506

Review 8.  Noncytolytic extraction of cell surface antigens using butanol.

Authors:  S J LeGrue
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies.

Authors:  H F Seigler; M K Wallack; C E Vervaert; J A Bash; K M Roberson; G M Stuhlmiller
Journal:  J Biol Response Mod       Date:  1989-02

10.  Dissociated and reconstituted subcellular alloantigen capable of stimulating mouse cytotoxic T lymphocytes in vitro.

Authors:  L D Fast; D P Fan
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

View more
  4 in total

1.  An attempt to induce "Graves' disease of the gonads" by immunizing mice with the luteinizing hormone receptor provides insight into breaking tolerance to self-antigens.

Authors:  Chun-Rong Chen; Holly A Aliesky; Basil Rapoport; Sandra M McLachlan
Journal:  Thyroid       Date:  2011-06-07       Impact factor: 6.568

Review 2.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

3.  Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Authors:  J J Bergers; W Den Otter; H F Dullens; C T Kerkvliet; D J Crommelin
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

4.  Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice.

Authors:  J J Bergers; W Den Otter; H F Dullens; J W De Groot; P A Steerenberg; M W Mimpen; D J Crommelin
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.